The Saliency platform utilizes proprietary algorithms to quickly build and also train AI models from a small number of de-identified images.
FREMONT, CA: Bioclinica, an integrated solutions provider of clinical life science and technology expertise, has acquired Silicon Valley-based Saliency. Bioclinica would integrate the company's cutting-edge AI technology into its Imaging Platform to support a growing portfolio of pharmaceutical as well as medical device clients. The integration will dramatically boost image QC and interpretation, allowing for rapid development of digital diagnostics as well as digital therapeutics.
"Clients rely on us for time-sensitive expert-level image interpretation for their clinical trials so they can focus on outcomes," stated Dan Gebow, PhD, Chief Innovation Officer at Bioclinica. "We evaluated a variety of medical imaging AI platforms and know the Saliency platform is head and shoulders above others in the market in its ability to deliver value for our clients."
The Saliency platform utilizes proprietary algorithms to quickly build and also train AI models from a small number of de-identified images. These newly created models can then be utilized to accurately and efficiently screen, redact, or interpret medical images to support a vast range of therapeutic areas. This capability will be embedded into Bioclinica's current as well as future imaging solutions in accordance with EU GDPR and other privacy regulations.
"This integration empowers industry stakeholders with the absolute latest in medical imaging technology by delivering custom AI models faster and with more accuracy," stated Kevin Thomas, MD/PhD, CEO of Saliency. "We are proud to combine our state-of-the-art cloud-based tools with Bioclinica'sunrivaled imaging expertise," added ŁukaszKidziński, PhD, Saliency's President and CTO.
The Saliency acquisition bolsters Bioclinica's position as the premier global provider of research image technology as well as services to sponsors and Clinical Research Organizations. The AI integration would create a perpetual learning system that is expected to enable Bioclinica to expand its portfolio and drive new revenue with its enhanced offering.